Loading stock data…
$13.21-0.02 (-0.15%)
Dr.
Dr. Reddy's Laboratories Limited in the Healthcare sector is trading at $13.21 with a market capitalization of $10.4B. Wall Street consensus targets $13.78 (5 analysts), implying a +4.3% move over the next 12 months. The stock is currently 16% below its 52-week high of $15.67, remaining 0.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $80.70B↑ | $75.16B↓ | $87.27B↓ | $88.05B↑ | $85.45B |
| Gross Profit | $37.54B↓ | $43.03B↓ | $46.81B↓ | $48.14B↓ | $48.63B |
| Operating Income | $3.03B↑ | $829.00M↓ | $14.33B↓ | $17.87B↑ | $16.84B |
| Net Income | $4.43B↑ | $2.21B↓ | $12.10B↓ | $14.37B↑ | $14.18B |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Ac...